All News
Filter News
Found 543 articles
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - February 03, 2023
2/3/2023
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced that the company granted equity awards to 4 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
KRAS Inhibitor Drug LUMAKRAS Sotorasib Krazati Adagrasib Market Forecast 2029
2/3/2023
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
-
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
2/2/2023
Verastem Oncology today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
-
Mirati Therapeutics to Participate in Two Upcoming February 2023 Healthcare Conferences
2/1/2023
Mirati Therapeutics, Inc., a targeted oncology company, will participate in two upcoming healthcare conferences.
-
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
1/24/2023
Verastem Oncology (Nasdaq: VSTM) today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).
-
Cue Biopharma Announces Chief Medical Officer Transition
1/23/2023
Cue Biopharma, Inc. (Nasdaq: CUE) announced today that Matteo Levisetti, M.D., senior vice president (SVP) of clinical development at Cue Biopharma, has been promoted to Chief Medical Officer (CMO) effective January 17, 2023.
-
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
1/19/2023
Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation.
-
Key Genetic Code Change Drives Common Lung Cancer Type
1/9/2023
A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might be treated.
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Jan 06, 2023
1/6/2023
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
NovoCure's novel cancer-fighting platform hits the mark in non-small cell lung cancer.
-
In a recently published study, MD Anderson researchers achieved curative responses in pancreatic cancer models by targeting checkpoints in T cells and myeloid suppressor cells.
-
Orthofix and SeaSpine Announce Completion of Merger of Equals to Create a Leading Global Spine and Orthopedics Company
1/4/2023
Orthofix Medical Inc. and SeaSpine Holdings Corporation announced the successful completion of their previously announced merger of equals following the approval of each company’s stockholders at respective special meetings of stockholders.
-
Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/22/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.
-
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer
12/21/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.
-
Verastem Oncology Appoints Rob Gagnon to Board of Directors
12/15/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.
-
Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - December 13, 2022
12/13/2022
Mirati Therapeutics, Inc. announced that the company granted equity awards to 11 new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
12/13/2022
Agilent Technologies Inc. announced that the U.S. Food and Drug Administration has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced non-small cell lung cancer patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM.
-
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
12/13/2022
QIAGEN has announced the U.S. Food and Drug Administration approval of its therascreen® KRAS RGQ PCR kit as a companion diagnostic test to Mirati Therapeutic’s drug KRAZATI® for non-small cell lung cancer.
-
As 2022 comes to its conclusion, the FDA has a handful of Prescription Drug User Fee Amendments still to wrap up. Here’s a look at that and more.